Jeffrey Robert Ajer Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jeffrey Robert Ajer is EVP, Chief Commercial Officer of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 66,767 shares of BMRN, which is worth approximately $5.5 Million. The most recent transaction as insider was on May 02, 2024, when has been sold 5,000 shares (Common Stock) at a price of $82.91 per share, resulting in proceeds of $414,550. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 66.8K

6.58% 3M change

1.46% 12M change

Total Value Held $5.5 Million

Jeffrey Robert Ajer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 02 2024	SELL Open market or private sale	$414,550 $82.91 p/Share	5,000 Reduced 6.97%	66,767 Common Stock
Apr 30 2024	BUY Grant, award, or other acquisition	$20,595 $68.65 p/Share	300 Added 0.42%	71,767 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$1,893,784 $83.87 p/Share	22,580 Reduced 24.01%	71,467 Common Stock
Mar 05 2024	SELL Open market or private sale	$348,280 $87.07 p/Share	4,000 Reduced 4.08%	94,047 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	37,243 Added 27.53%	98,047 Common Stock
Aug 16 2023	SELL Open market or private sale	$450,000 $90.0 p/Share	5,000 Reduced 7.6%	60,804 Common Stock
Apr 28 2023	BUY Grant, award, or other acquisition	$21,267 $66.88 p/Share	318 Added 0.48%	65,804 Common Stock

Mar 16 2023	SELL Payment of exercise price or tax liability	$1,915,839 $93.41 p/Share	20,510 Reduced 23.85%	65,486 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$348,415 $87.74 p/Share	3,971 Reduced 4.41%	85,996 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	10,110 Added 10.1%	89,967 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	38,769 Added 32.68%	79,857 Common Stock
Jan 25 2023	SELL Open market or private sale	$5,679,100 $115.9 p/Share	49,000 Reduced 54.39%	41,088 Common Stock
Jan 25 2023	BUY Exercise of conversion of derivative security	$3,322,690 $67.81 p/Share	49,000 Added 35.23%	90,088 Common Stock
Nov 02 2022	SELL Open market or private sale	$258,360 $86.12 p/Share	3,000 Reduced 6.8%	41,088 Common Stock
Aug 11 2022	SELL Open market or private sale	$286,860 $95.62 p/Share	3,000 Reduced 6.37%	44,088 Common Stock
Jun 03 2022	SELL Payment of exercise price or tax liability	$544,057 $77.49 p/Share	7,021 Reduced 12.98%	47,088 Common Stock
May 26 2022	SELL Open market or private sale	$103,254 $78.94 p/Share	1,308 Reduced 2.36%	54,109 Common Stock
Apr 29 2022	BUY Grant, award, or other acquisition	$21,219 $62.41 p/Share	340 Added 0.61%	55,417 Common Stock
Apr 13 2022	SELL Open market or private sale	$97,315 $82.47 p/Share	1,180 Reduced 2.1%	55,077 Common Stock
Mar 30 2022	SELL Open market or private sale	$109,872 $79.56 p/Share	1,381 Reduced 2.4%	56,257 Common Stock
Mar 29 2022	SELL Open market or private sale	$128,518 $79.43 p/Share	1,618 Reduced 2.73%	57,638 Common Stock
Mar 23 2022	SELL Open market or private sale	$501,230 $81.78 p/Share	6,129 Reduced 9.37%	59,256 Common Stock
Mar 22 2022	SELL Open market or private sale	$167,913 $81.0 p/Share	2,073 Reduced 3.07%	65,385 Common Stock
Mar 16 2022	SELL Payment of exercise price or tax liability	$103,887 $80.72 p/Share	1,287 Reduced 1.87%	67,458 Common Stock
Mar 15 2022	SELL Payment of exercise price or tax liability	$658,877 $78.27 p/Share	8,418 Reduced 10.91%	68,745 Common Stock

Also insider at

NKTR

NEKTAR THERAPEUTICS Healthcare

Director

JRA